Navigation Links
Myoderm Selects Tracie DiPasquale To Lead CentralSource
Date:1/8/2013

Norristown, PA (PRWEB) January 08, 2013

Myoderm, a global leader in sourcing commercial drugs for clinical trials, is pleased to announce that Tracie DiPasquale has joined the company as Director, CentralSource. She will work out of Myoderm’s US office.

Myoderm is fortunate to have someone with Tracie’s background and qualifications to direct CentralSource, the company’s turnkey sourcing, distribution, and management service that supplies individual sites directly on an as-needed basis. For over a decade, she managed business development efforts and implemented supply chain strategies for leading pharmaceutical firms, including Pfizer and Almac. Her diversified experience with both large and small pharmaceutical companies gives her the insight and flexibility to exceed clients’ needs.

A graduate of the University of Pittsburgh, with a B.Sc. degree in Natural Sciences and a minor in Biology, Tracie offers Myoderm customers a unique understanding of global clinical site drug supply management and oversight issues.

Mike Cohen, Managing Director of Myoderm, says, “Tracie’s experience from both the service and client sides gives her an invaluable perspective on sourcing issues and makes her a superb advocate for Myoderm clients.”

About Myoderm
Myoderm is a leader in the sourcing, distribution, and management of commercial pharmaceutical products and supplies for clinical trials and biosimilar research. The company’s clients span the globe and include biotech, CROs, clinical trial packagers, and the majority of the world’s top10 pharmaceutical companies. With its deep expertise, customized solutions, and commitment to personalized service, Myoderm provides the optimal drug supply solution for global clinical studies.

Read the full story at http://www.prweb.com/releases/2013/1/prweb10292730.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. UCAN Selects Defran Systems to Support its Wide Range of Youth and Family Programs
2. President Obama selects Rutgers cell biologist Nihal Altan-Bonnet to receive prestigious award
3. The Gerontological Society of America Selects 2012 Fellows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... ... The Radiology Business Management Association (RBMA) is pleased to announce ... process has been in place since the RBMA was founded in 1968 with all ... Jim Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the chief executive officer for ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... and College of Urgent Care Medicine will host industry leaders for the annual ... will help those in the industry adapt to the issues currently affecting urgent ...
(Date:4/28/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, has ... which He does not. Yisrayl says with so many titles and names for the ... he says with a little Scripture, backed with a lot of research, the truth is ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... skincare and advanced nutraceutical supplements, through its Nova Skin Sciences division, recently ... hydrating benefits of a moisturizer with the power of an anti-aging concentrate. ...
(Date:4/28/2017)... ... 2017 , ... Christie Medical Holdings, Inc. , with its market-leading ... Medical Inc. , a leader in infusion therapy and pain management. , Intravenous ... percent of hospital patients receiving a peripheral IV catheter as part of their treatment ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , Tenn. and DALLAS , April 19, ... Inc., announced that the first patients in ... EndoStim device in the Lower Esophageal Sphincter Stimulation for ... minimally-invasive implantable device designed to provide long-term reflux control ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-naïve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
(Date:4/18/2017)... 18, 2017 Research and Markets has announced ... report to their offering. ... global arthroscopy devices market to grow at a CAGR of 6.35% ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
Breaking Medicine Technology: